Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Equity Ratio (2016 - 2025)

Voyager Therapeutics' Equity Ratio history spans 11 years, with the latest figure at 0.78 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 1.91% year-over-year to 0.78; the TTM value through Dec 2025 reached 0.78, up 1.91%, while the annual FY2025 figure was 0.78, 1.91% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.78 at Voyager Therapeutics, up from 0.76 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.78 in Q4 2025 and bottomed at 0.32 in Q2 2022.
  • The 5-year median for Equity Ratio is 0.64 (2023), against an average of 0.61.
  • The largest annual shift saw Equity Ratio soared 131.77% in 2021 before it crashed 40.89% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.49 in 2021, then dropped by 24.47% to 0.37 in 2022, then skyrocketed by 81.64% to 0.67 in 2023, then grew by 13.37% to 0.76 in 2024, then grew by 1.91% to 0.78 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Equity Ratio are 0.78 (Q4 2025), 0.76 (Q3 2025), and 0.76 (Q2 2025).